1 |
Javier, D. : Review of the molecular pharmacology of losartan and its possiblerelevance to stroke prevention in patients with hypertension. Clinical Therapeutics. 28, 832 (2006)
DOI
PUBMED
ScienceOn
|
2 |
McIntyre, M., Caffe, S. E., Michalak, R. A. and Reid, J. L. : Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension. Pharmacol. Ther. 74, 181 (1997)
DOI
ScienceOn
|
3 |
Inagami, T., Iwai, N., Sasaki, K., Yamamo, Y., Bardhan, S., Chaki, S., Guo, D. F. and Furuta, H. : Cloning, expression and regulation of angiotensin II receptors. J. Hypertens. 8, 713 (1992)
|
4 |
Lo, M. W., Goldberg, M. R., McCrea, J. B., Lu, H., Furtek, C. I. and Bjornsson, T. D. : Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP-3174 in humans. Clin. Pharmacol. Ther. 58, 641 (1995)
DOI
ScienceOn
|
5 |
Kaukonen, K. M., Olkkola, K. T. and Neuvonen, P. J. : Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur. J. Clin. Pharmacol. 53, 445 (1998)
DOI
ScienceOn
|
6 |
McCrea, J. B., Cribb, A., Rushmore, T., Osborne, B., Gillen, L., Lo, M. W., Waldman, S., Bjornsson, T., Spielberg, S. and Goldberg, M. R. : Phenotypic and genotypic investigations of a healthy volunteer deficient in the conversion of losartan to its active metabolite E-3174. Clin. Pharmacol. Ther. 65, 348 (1999)
DOI
ScienceOn
|
7 |
Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)
DOI
ScienceOn
|
8 |
Gan, L. S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3ALike cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug. Metab. Dispos. 24, 344 (1996)
|
9 |
Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998)
DOI
PUBMED
|
10 |
Reynolds, J. E. F. : Martindale - The extra pharmacopeia. Pharmaceutical Press. London (1993)
|
11 |
Hodek, P., Trefil, P. and Stiborova, M. : Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem. Biol. Interact. 139, 1 (2002)
DOI
ScienceOn
|
12 |
Bardelmeijer, H. A., Beijnen, J. H., Brouwer, K. R., Rosing, H., Nooijen, W. J., Schellens, J. H. and Van Tellingen, O. : Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein. Clin. Cancer Res. 6, 4416 (2000)
|
13 |
Takanaga, H., Ohnishi, A., Matsuo, H. and Sawada, Y. : Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol. Pharm. Bull. 21, 1062 (1998)
DOI
PUBMED
ScienceOn
|
14 |
Eagling, V. A., Profit, L. and Back, D. J. : Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br. J. Clin. Pharmacol. 48, 543 (1999)
DOI
ScienceOn
|
15 |
Ho, P. C., Saville, D. J. and Wanwimolruk, S. : Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J. Pharm, Pharm, Sci. 4, 217 (2001)
|
16 |
Meadowcroft, A. M., Williamson, K. M., Patterson, J. H., Hinderliter, A. L. and Pieper, J. A. : The effects of fluvastatin, a CYP2C9 inhibitor, on losartan pharmacokinetics in healthy volunteers. J. Clin. Pharmacol. 39, 418 (1999)
DOI
ScienceOn
|
17 |
Kim, D. H., Jung, E. A., Sohng, I. S., Han, J. A., Kim, T. H. and Han, M. J. : Intestinal bacterial metabolism of flavonoids and its relation to some biological activities. Arch. Pharm. Res. 21, 17 (1998)
과학기술학회마을
DOI
PUBMED
|
18 |
Choi, J. S. and Shin, S. C. : Enhanced paclitaxel bioavailability after oral coadministration of paclitaxel prodrug with naringin to rats. Int. J. Pharm. 23, 149 (2005)
|
19 |
Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999)
DOI
ScienceOn
|
20 |
Soldner, A., Christians, U., Susanto, M., Wacher, V. J., Silverman, J. A. and Benet, L. Z. : Grapefruit juice activates Pglycoprotein-mediated drug transport. Pharm. Res. 16, 478 (1999)
DOI
ScienceOn
|
21 |
Stearns, R. A., Chakravarty, P. K., Chen, R. and Chiu, S. H. : Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. Drug Metab. Dispos. 23, 207 (1995)
|
22 |
Nijveldt, R. J., Van Nood, E., Van Hoorn, D. E. C., Boelens, P. G., Van Norren, K. and Van Leeuwen, P. A. M. : Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 74, 418 (2001)
|
23 |
Stearns, R. A., Miller, R. R., Doss, G. A., Chakravarty, P. K., Rosegay, A., Gatto, G. J. and Chiu, S. H. : The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices. Drug. Metab. Dispos. 20, 281 (1992)
|
24 |
Gottesman, M. M. and Pastan, I. : Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62, 385 (1993)
DOI
ScienceOn
|
25 |
Kim, H. J. and Choi, J. S. : Effectof naringin on the pharmacolinetics of verapamil and one of its metabolites, norverapamil, in rabbits. Bio. Drug. Dispos. 26, 295 (2005)
DOI
ScienceOn
|
26 |
Dixon, R. A. and Steele, C. : Flavonoids and isoflavonoids-gold mine for metabolic engineering. Trends Plant Sci. 4, 394 (1999)
DOI
ScienceOn
|
27 |
Watkins, P. B. : The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Drug. Deliv. Rev. 27, 161 (1996)
DOI
ScienceOn
|
28 |
The Merck Index, 12th Edition, Merck and Co. Inc., Rahway, USA. pp. 6512 (1996)
|
29 |
Soldner, A., Hildegard, S. L. and Mutschler, E. : HPLC assays to simultaneously determine the angiotensin-AT1 antagonist losartan as well as its main and active metabolite EXP-3174 in biological material of humans and rats. Journal of Pharmaceutical and Biomedical Analysis. 16, 863 (1998)
DOI
ScienceOn
|
30 |
Yun, C. H., Lee, H. S., Lee, H., Rho, J. K., Jeong, H. G. and Guengerich, F. P. : Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174. Drug. Metab. Dispos. 23, 285 (1995)
|
31 |
Ito, K., Kusuhara, H. and Sugiyama, Y. : Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm. Res. 16, 225 (1999)
DOI
ScienceOn
|
32 |
Dupuy, J., Larrieu, G., Sutra, J. F., Lespine, A. and Alvinerie, M. : Enhancement of moxidectin bioavailability in lamb by a natural flavonoid: quercetin. Vet. Parasitol. 112, 337 (2003)
DOI
ScienceOn
|
33 |
Wacher, V. H., Silverman, J. A., Zhang, Y. and Benet, L. Z. : Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J. Pharm. Sci. 87, 1322 (1998)
DOI
PUBMED
|
34 |
Zhang, H., Wong, C. W., Coville, P. G. and Wanwimolruk, S. : Effect of the grapefruit flavonoid naringin on pharmacokinetics of quinine in rats. Drug Metabol. Drug Interact. 17, 351 (2000)
PUBMED
|
35 |
Wacher, V. J., Salphati, L. and Benet, L. Z. : Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv. Drug. Deliv. Rev. 46, 89 (2001)
DOI
ScienceOn
|
36 |
Gan, L.-S. L., Moseley, M. A., Khosla, B., Augustijns, P. F., Bradshaw, T. P., Hendren, R. W. and Thakker, D. R. : CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab. Dispos. 24, 344 (1996)
|
37 |
Choi, J. S. and Han, H. K. : Enhenced oral exposure of diltiazem by the concomitant use of naringin in rats. Int. J. Pharm. 30, 122 (2005)
|
38 |
Zarghi, A., Foroutan, S. M., Shafaati, A. and Khoddam, A. : A rapid HPLC method for the determination of losartan in human plasma using a monolithic column. Arzneimittelforschung. 55, 569 (2005)
PUBMED
|
39 |
Doostdar, H., Burke, M. D. and Mayer, R. T. : Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31 (2000)
DOI
PUBMED
ScienceOn
|